Preview

Rational Pharmacotherapy in Cardiology

Advanced search

POSSIBILITY OF ANGIOTENSIN RECEPTOR BLOCKERS IN OPTIMIZING OF ANTIHYPERTENSIVE PHARMACOTHERAPY IN PATIENTS AFTER STROK

https://doi.org/10.20996/1819-6446-2013-9-6-678-681

Full Text:

Abstract

Current possibilities of AT1 receptor blockers (ARBs), such as candesartan, for optimization of antihypertensive therapy in stroke patients are presented in the article. ARBs are original drugs that effect to the delicate balance of pressor and depressor neurohormonal systems. They also have cerebroprotective action and are the drugs of choice for primary and secondary prevention of stroke in hypertensive patients

About the Author

Z M. Sizova
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation


References

1. Shalnova SA, Balanova YA, Konstantinov VV et al. Hypertension prevalence, awareness, antihypertensive drugs and treatment efficacy among the population of the Russian Federation. Russian Cardiology Journal 2006; (4): 45-50. Russian (Шальнова С.А., Баланова Ю.А., Константинов В. В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский Кардиологический Журнал 2006; (4): 45-50).

2. National guidelines for the diagnosis and treatment of hypertension (4th revision) . Sistemnie Gypertensii 2010 (3) : 5-26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертензии (четвертый пересмотр). Системные гипертензии 2010; (3): 5-26).

3. Ezzati M, Lopez A, Rodgers A, Vander Hoorn S et al. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Ge-neva: World Health Organization; 2004.

4. Lees KR, Bath PM, Naylor AR. ABC of arterial and venous disease. Secondary prevention of transient ischaemic attack and stroke. BMJ 2000; 320:991-4;

5. Hankey GJ, Warlow CP. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999;354:1457-1463;

6. Drapkina OM, Mussina NP, Kozlova EV. Role in the prevention of stroke internist. Russian Medical Jour- nal 2009; 18: 1198-205. Russian (Драпкина О.М., Мусина Н.П., Козлова Е.В. Роль интерниста в профилактике инсульта. Русский Медицинский Журнал 2009; 18: 1198-205).

7. Parfenov VA. Risk factors and secondary prevention of ischemic stroke. Atmosphere. Nervous Diseases 2007; (1): 2-8. Russian (Парфенов В.А. Факторы риска и вторичная профилактика ишемического инсульта. Атмосфера. Нервные болезни 2007;(1): 2-8).

8. Chalmers J., MacMahon S., Anderson C. et al. Clinician’s manual on blood pressure and stroke prevention. 2nd ed., London : Science Press; 2000

9. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31(7):1281-357

10. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265(24):3255-64.

11. Faulhaber HD. Results of the SYST-EUR study. Isolated systolic hypertension and calcium antagonists. Fortschr Med 1997;115(32):45-6.

12. Olbinskaya LI, Morozova TE, Sizova ZM, Vartanova OA. Pharmacotherapy and other chronic cardio- vascular disease: a guide for physicians. Moscow: Meditsina; 2006. Russian (Ольбинская Л.И., Морозова Т.Е., Сизова Ж.М., Вартанова О.А. и др. Фармакотерапия хронических сердечно-сосудистых заболеваний: Руководство для врачей. М.: Медицина; 2006).

13. Gorokhova SG, Sizova ZM. Pharmacotherapy of chronic heart failure in outpatient physician practice. Moscow: Medpraktika-M; 2008. Russian (Горохова С.Г., Сизова Ж.М. Фармакотерапия хронической сердечной недостаточности в амбулаторно-поликлинической практике врача. М.: Медпрактика-М; 2008).

14. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet 2002; 359: 995-1003.

15. Drapkina OM, Kozlova EV. Fitting angiotensin receptor antagonists in treating cardiovascular diseases. The EFFEKT Study: Lorista use in patients with mild to moderate hypertension in a real clinical practice. Russian Journal of Medicine 2011; (8): 10-4. Russian (Драпкина О.М., Козлова Е.В. Место антагонистов рецепторов ангиотензина в лечении сердечно-сосудистых заболеваний. Исследование ЭФФЕКТ: применение Лористы у пациентов с мягкой и умеренной артериальной гипертензией в условиях реальной клинической практики. Российский Медицинский Журнал 2011; (8): 10-4).

16. Schrader J, Luders S, Kulschewski A. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218-26.

17. Wang OD, Sjoquist PO. Effects of the insurmountable angiotensin II AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts. Eur J Pharmacol 1999; 380: 13-21.

18. Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1 -receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004;44(6):1175-80.

19. Schrader J, Luders S, Kulschewski A, et al. The ACCESS study. Evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699-703.


For citation:


Sizova Z.M. POSSIBILITY OF ANGIOTENSIN RECEPTOR BLOCKERS IN OPTIMIZING OF ANTIHYPERTENSIVE PHARMACOTHERAPY IN PATIENTS AFTER STROK. Rational Pharmacotherapy in Cardiology. 2013;9(6):678-681. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-6-678-681

Views: 409


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)